Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Research analysts at HC Wainwright raised their Q1 2025 EPS estimates for shares of Microbot Medical in a research note issued to investors on Thursday, April 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.15). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.40) EPS.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02).
Microbot Medical Price Performance
NASDAQ MBOT traded up $0.03 during trading hours on Monday, hitting $2.49. The company's stock had a trading volume of 2,865,993 shares, compared to its average volume of 2,080,807. Microbot Medical has a 12 month low of $0.82 and a 12 month high of $3.38. The company's 50 day simple moving average is $1.69 and its two-hundred day simple moving average is $1.41. The company has a market cap of $86.51 million, a P/E ratio of -3.11 and a beta of 1.40.
Institutional Trading of Microbot Medical
A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC bought a new position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned 0.52% of Microbot Medical at the end of the most recent quarter. 16.30% of the stock is currently owned by institutional investors.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
